[go: up one dir, main page]

PL1608368T3 - Kompozycje farmaceutyczne zawierające kombinację rapamycyny lub jej pochodnej i pimekrolimusa do leczenia choroby zapalenia jelit - Google Patents

Kompozycje farmaceutyczne zawierające kombinację rapamycyny lub jej pochodnej i pimekrolimusa do leczenia choroby zapalenia jelit

Info

Publication number
PL1608368T3
PL1608368T3 PL04720871T PL04720871T PL1608368T3 PL 1608368 T3 PL1608368 T3 PL 1608368T3 PL 04720871 T PL04720871 T PL 04720871T PL 04720871 T PL04720871 T PL 04720871T PL 1608368 T3 PL1608368 T3 PL 1608368T3
Authority
PL
Poland
Prior art keywords
pimecrolimus
ibd
rapamycin
derivative
treatment
Prior art date
Application number
PL04720871T
Other languages
English (en)
Inventor
Henrietta Moore
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33032928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1608368(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0306070A external-priority patent/GB0306070D0/en
Priority claimed from GB0306868A external-priority patent/GB0306868D0/en
Priority claimed from GB0319226A external-priority patent/GB0319226D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1608368T3 publication Critical patent/PL1608368T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
PL04720871T 2003-03-17 2004-03-16 Kompozycje farmaceutyczne zawierające kombinację rapamycyny lub jej pochodnej i pimekrolimusa do leczenia choroby zapalenia jelit PL1608368T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0306070A GB0306070D0 (en) 2003-03-17 2003-03-17 Organic compounds
GB0306868A GB0306868D0 (en) 2003-03-25 2003-03-25 Organic compounds
GB0319226A GB0319226D0 (en) 2003-08-15 2003-08-15 Organic compounds
PCT/EP2004/002714 WO2004082681A1 (en) 2003-03-17 2004-03-16 Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation- and ummunologically-mediated diseases
EP04720871A EP1608368B8 (en) 2003-03-17 2004-03-16 Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammatory bowel disease (ibd)

Publications (1)

Publication Number Publication Date
PL1608368T3 true PL1608368T3 (pl) 2009-03-31

Family

ID=33032928

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04720871T PL1608368T3 (pl) 2003-03-17 2004-03-16 Kompozycje farmaceutyczne zawierające kombinację rapamycyny lub jej pochodnej i pimekrolimusa do leczenia choroby zapalenia jelit

Country Status (25)

Country Link
US (1) US20060154952A1 (pl)
EP (1) EP1608368B8 (pl)
JP (1) JP2006515017A (pl)
KR (1) KR100855140B1 (pl)
AR (1) AR043504A1 (pl)
AT (1) ATE409479T1 (pl)
AU (1) AU2004222563B2 (pl)
BR (1) BRPI0408423A (pl)
CA (2) CA2633287A1 (pl)
CL (1) CL2004000535A1 (pl)
DE (1) DE602004016830D1 (pl)
EC (1) ECSP056006A (pl)
ES (1) ES2315648T3 (pl)
HR (1) HRP20050800A2 (pl)
IS (1) IS8028A (pl)
MA (1) MA27671A1 (pl)
MX (1) MXPA05009934A (pl)
MY (1) MY137868A (pl)
NO (1) NO20054778L (pl)
PE (1) PE20050313A1 (pl)
PL (1) PL1608368T3 (pl)
PT (1) PT1608368E (pl)
TN (1) TNSN05197A1 (pl)
TW (2) TW200835484A (pl)
WO (1) WO2004082681A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007005153A (es) * 2004-10-28 2007-06-26 Wyeth Corp Uso de un inhibidor del mtor en el tratamiento de leiomioma del utero.
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
JP5647098B2 (ja) * 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
MX2011007647A (es) 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
RU2449806C1 (ru) * 2010-11-30 2012-05-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ лечения красного плоского лишая слизистой оболочки полости рта
ES2797376T3 (es) 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
KR102256576B1 (ko) 2013-10-08 2021-05-27 에이아이 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
WO2015154084A1 (en) * 2014-04-04 2015-10-08 Lam Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
RU2732908C2 (ru) 2014-10-07 2020-09-24 ЭйАй ТЕРАПЬЮТИКС, ИНК. Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии
US10851144B2 (en) 2015-04-10 2020-12-01 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
WO2020010073A1 (en) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10299040I2 (de) * 1989-11-09 2006-08-24 Novartis Ag Heteroatome enthaltende tricyclische Verbindungen
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
DK0956034T3 (da) * 1996-07-30 2002-12-16 Novartis Ag Farmaceutiske præparater til behandling af transplantatafstødning, autoimmune eller inflammatoriske tilstande omfattende cyclosporin A og 40-O-(2-hydroxyethyl)-rapamycin
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
CN1543345A (zh) * 2001-05-09 2004-11-03 诺瓦提斯公司 使用匹美莫司进行选择性免疫调节的方法
JP2005514411A (ja) * 2002-01-10 2005-05-19 ノバルティス アクチエンゲゼルシャフト ラパマイシンおよびその誘導体を含む血管疾患の予防および処置用薬剤送達システム
JP5106750B2 (ja) * 2002-05-09 2012-12-26 ヘモテック アーゲー 血液適合性の様式で表面をコーティングするための化合物および方法

Also Published As

Publication number Publication date
AR043504A1 (es) 2005-08-03
CL2004000535A1 (es) 2005-01-14
TW200835484A (en) 2008-09-01
MXPA05009934A (es) 2006-03-21
EP1608368A1 (en) 2005-12-28
ES2315648T3 (es) 2009-04-01
TW200503703A (en) 2005-02-01
MY137868A (en) 2009-03-31
US20060154952A1 (en) 2006-07-13
WO2004082681A1 (en) 2004-09-30
NO20054778D0 (no) 2005-10-17
CA2633287A1 (en) 2004-09-30
AU2004222563B2 (en) 2006-11-02
CA2517671A1 (en) 2004-09-30
KR100855140B1 (ko) 2008-08-28
HK1086743A1 (en) 2006-09-29
AU2004222563A1 (en) 2004-09-30
TNSN05197A1 (en) 2007-06-11
PT1608368E (pt) 2009-01-27
ECSP056006A (es) 2006-01-27
NO20054778L (no) 2005-12-19
JP2006515017A (ja) 2006-05-18
MA27671A1 (fr) 2005-12-01
IS8028A (is) 2005-09-15
EP1608368B1 (en) 2008-10-01
ATE409479T1 (de) 2008-10-15
KR20050110023A (ko) 2005-11-22
BRPI0408423A (pt) 2006-03-21
DE602004016830D1 (de) 2008-11-13
WO2004082681B1 (en) 2004-11-25
PE20050313A1 (es) 2005-06-14
HRP20050800A2 (en) 2006-11-30
EP1608368B8 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
IL152127A0 (en) Probiotic compositions for the treatment of inflammatory bowel disease
GB0320382D0 (en) Pharmaceutical compositions
GB0327723D0 (en) Pharmaceutical compositions
ZA200604352B (en) Azepinondole derivatives as pharmaceutical agents
EP1592384A4 (en) COP 1 FOR THE TREATMENT OF INFLAMMABLE ENDURANCE
EP1592384A3 (en) Cop 1 for treatment of inflammatory bowel diseases
ZA200800448B (en) Methods and compositions for the prevention and treatment of inflammatory disease
PT1701698E (pt) Composição farmacêutica para a administração oral de cci-779
IL172647A0 (en) Compositions of lipopeptide antibiotic derivatives and methods of use thereof
IL183986A0 (en) Pharmaceutical compounds and compositions
IL182703A (en) Pharmaceuticals containing camptothecin derivatives
ZA200801678B (en) Treatment of inflammatory bowel disease
PT1608368E (pt) Composições farmacêuticas compreendendo uma combinação de rapamicina ou seu derivado e pimecrolimus para o tratamento da doença inflamatória do intestino (dii).
GB0300531D0 (en) Pharmaceutical compositions
EP1680145A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
IL170313A (en) Diarylcycloalkyl derivatives and pharmaceutical compositions comprising them
ZA200805419B (en) Compositions and methods for preventing or treating inflammatory bowel disease
EP1648411A4 (en) PHARMACEUTICAL COMPOSITIONS
ZA200605080B (en) Pharmaceutical compositions
IL175498A0 (en) Pharmaceutical compositions containing n-hydroxypiperidine derivatives
ZA200707955B (en) Methods and pharmaceutical compositions for the treatment of neurological damage
PL1687006T3 (pl) Kompozycje farmaceutyczne do leczenia zaburzeń czynności nerek
EP1803452A4 (en) ESTER DERIVATIVE AND ITS PHARMACEUTICAL USE THEREOF
GB0305579D0 (en) Pharmaceutical compositions
IL177105A0 (en) Coumarin derivative and use thereof